Literature DB >> 11960372

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.

Guilian Niu1, Kenneth L Wright, Mei Huang, Lanxi Song, Eric Haura, James Turkson, Shumin Zhang, Tianhong Wang, Dominic Sinibaldi, Domenico Coppola, Richard Heller, Lee M Ellis, James Karras, Jacqueline Bromberg, Drew Pardoll, Richard Jove, Hua Yu.   

Abstract

Non-receptor and receptor tyrosine kinases, such as Src and EGF receptor (EGFR), are major inducers of vascular endothelial growth factor (VEGF), one of the most potent mediators of angiogenesis. While tyrosine kinases signal through multiple pathways, signal transducer and activation of transcription 3 (Stat3) is a point of convergence for many of these and is constitutively activated with high frequency in a wide range of cancer cells. Here, we show that VEGF expression correlates with Stat3 activity in diverse human cancer cell lines. An activated Stat3 mutant (Stat3C) up-regulates VEGF expression and stimulates tumor angiogenesis. Stat3C-induced VEGF up-regulation is abrogated when a Stat3-binding site in the VEGF promoter is mutated. Furthermore, interrupting Stat3 signaling with dominant-negative Stat3 protein or Stat3 antisense oligonucleotide in tumor cells down-regulates VEGF expression. Consistent with an important role of Stat3 in VEGF up-regulation induced by various oncogenic tyrosine kinases, v-Src-mediated VEGF expression is inhibited when Stat3 signaling is blocked. Moreover, chromatin immunoprecipitation assays indicate that Stat3 protein binds to the VEGF promoter in vivo and mutation of a Stat3-binding site in the VEGF promoter abrogates v-Src-induced VEGF promoter activity. These studies provide evidence that the VEGF gene is regulated directly by Stat3 protein, and indicate that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960372     DOI: 10.1038/sj.onc.1205260

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  448 in total

1.  Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3.

Authors:  Hong Yue; Kuniyoshi Tanaka; Tatsuhiko Furukawa; Sadashiva S Karnik; Wei Li
Journal:  Biochim Biophys Acta       Date:  2012-06-02

2.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer.

Authors:  Bao-He Zhu; Hua-Yun Chen; Wen-Hua Zhan; Cheng-You Wang; Shi-Rong Cai; Zhao Wang; Chang-Hua Zhang; Yu-Long He
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

4.  STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo.

Authors:  Aws Alshamsan; Samar Hamdy; Azita Haddadi; John Samuel; Ayman O S El-Kadi; Hasan Uludağ; Afsaneh Lavasanifar
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

5.  Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway.

Authors:  Xiaofang Xu; Yuping Zhu
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

6.  Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

Authors:  Verena von Felbert; Francisco Córdoba; Jakob Weissenberger; Claudio Vallan; Masashi Kato; Izumi Nakashima; Lasse Roger Braathen; Joachim Weis
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells.

Authors:  Zheng-Long Yuan; Ying-Jie Guan; Lijuan Wang; Wenyi Wei; Agnes B Kane; Y Eugene Chin
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

8.  Gadd45a suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway.

Authors:  Fang Yang; Weimin Zhang; Dan Li; Qimin Zhan
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

9.  mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.

Authors:  Stefan Thiem; Thomas P Pierce; Michelle Palmieri; Tracy L Putoczki; Michael Buchert; Adele Preaudet; Ryan O Farid; Chris Love; Bruno Catimel; Zhengdeng Lei; Steve Rozen; Veena Gopalakrishnan; Fred Schaper; Michael Hallek; Alex Boussioutas; Patrick Tan; Andrew Jarnicki; Matthias Ernst
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

Review 10.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.